Related by context. All words. (Click for frequent words.) 66 Gentamicin Surgical Implant 66 MKC# MT 66 Matrix Phase 2b 66 selectin antagonist 66 Initiates Phase II 66 delivers fluocinolone acetonide FA 66 RANK Ligand inhibitor 66 intravesical infusion therapy 65 6 sulfatase 65 XL# anticancer compounds 65 INSPIRE Trial Phase III 65 3 registrational trial 65 Telik logo TELINTRA 65 CEL SCI Phase III 65 pharmacogenomic translational research 65 Combination REOLYSIN R 65 Biopharmaceuticals AG 65 dependent kinase inhibitor 65 ABL inhibitor completing 65 AAG geldanamycin analog 64 initiated Phase Ib 64 pralatrexate injection folate analogue 64 TELINTRA R 64 Frozen Shoulder syndrome Adhesive 64 recombinant PSMA vaccine 64 markets Testim ® 64 rALLy clinical trial 64 candidate REP# 64 phase IIb clinical 64 Initiate Phase 64 evaluating picoplatin 64 Oral Calcitonin 64 Crofelemer budesonide foam 64 unique alkylating agent 64 Initiates Enrollment 64 ADVANCE ILLUMINATE 64 adecatumumab MT# 64 IMPACT DCM trial 64 oral dihydropyrimidine dehydrogenase DPD 64 Excellarate TM 64 VEGFR2 inhibitor 63 alvespimycin 63 NMT Medical Announces 63 TM pralatrexate injection 63 telomerase inhibitor drug 63 Commences Phase 63 ® bortezomib 63 initiate multicenter 63 BRIM3 63 IMPDH inhibitor 63 PDX pralatrexate 63 imetelstat GRN#L 63 R sorafenib tablets 63 dilated cardiomyopathy DCM 63 Trastuzumab DM1 63 MKC# MKC# PP 63 IIb clinical trial 63 LymphoStat B belimumab 63 overactive bladder AA# 63 topical antifungal product 63 class anticancer quinolone 63 oral picoplatin 63 accumulate preferentially 63 Initiates Phase III 63 Personalized Immunotherapy 62 evaluating satraplatin 62 humanized therapeutic 62 CG# oncolytic virus 62 Phase #b/#a clinical 62 Phase IIIb clinical 62 includes TOLAMBA TM 62 Pruvel TM 62 evaluating Prochymal 62 product platforms AZX# 62 Phase 2b MATRIX 62 Salix Pharmaceuticals Announces 62 BRIM2 62 PI3K/Akt pathway inhibitor 62 Amigal TM 62 Phase Ib II 62 modified glutathione analog 62 refractory chronic lymphocytic 62 Meets Primary Endpoint 62 sapacitabine CYC# 62 Empatic ™ 62 R vitespen 62 anti VEGF aptamer 62 opioid induced bowel dysfunction 62 ALN VSP Phase 62 evaluating tesamorelin 62 Quinamed R 62 Phase Ib IIa 62 candidates Azedra TM 62 Chrysalin r rusalatide acetate 62 Completes Patient Enrollment 62 PROVENGE ® 62 Phase III Pivotal 62 Submits Biologics License Application 62 HuMax TAC 62 IL# PE#QQR 62 clinical trials Archexin 62 EGFr humanized monoclonal antibody 62 Acetavance TM intravenous acetaminophen 62 hypoxia activated prodrug 62 CRMD# 62 KRYSTEXXA TM pegloticase 62 GVAX ® 62 vinorelbine tartrate 62 Randomized Phase II 62 GATTEX ™ 62 huC# DM4 62 potent topoisomerase II 62 novel therapeutic antibodies 62 PROTECT AF 62 Dose Ranging 61 virus HCV protease inhibitor 61 GetGoal Phase III 61 Hsp# Inhibitor 61 albiglutide 61 4SC AG ISIN DE# 61 cardiac myosin activator omecamtiv 61 Presents Positive 61 recurrent metastatic ovarian cancer 61 FOLOTYN ® 61 comparing XIENCE V 61 multicenter Phase II 61 lorvotuzumab mertansine 61 European Sepsis Trial 61 Cloretazine ® 61 Enrolls First 61 Romidepsin 61 TKB# 61 R roscovitine CDK cyclin 61 Zemiva ™ 61 HCV RNA polymerase 61 Patient Enrollment 61 acyclovir Lauriad R 61 Pivotal Trial 61 catheter occlusion 61 Phase 2b Clinical Trial 61 Successfully Completes Phase 61 IgG1 monoclonal antibody 61 cancer neuroendocrine tumor 61 evaluating satraplatin plus 61 generation rotary VAD 61 SPL# Gel vaginal microbicide 61 both intercalates DNA 61 randomized controlled Phase 61 Dementia Related Psychosis 61 multicenter Phase III 61 Completes Enrollment 61 non nucleoside inhibitor 61 Bayer HealthCare Onyx Pharmaceuticals 61 Vascular Disrupting Agent 61 solid tumors ZYBRESTAT 61 mertansine 61 Staphylococcus aureus Immune Globulin 61 Achieves Primary Endpoint 61 R bortezomib 61 novel antimitotic agent 61 novel emulsion formulation 61 lintuzumab SGN 61 transmucosal delivery system 61 ® decitabine 61 CYT# potent vascular disrupting 61 serine protease inhibitor CU# 61 PresbyLens ® 61 phase IIa clinical 61 IAP inhibitor 61 liver resection surgeries 61 Initiates Clinical Trial 61 Second Pivotal Phase 61 evaluating bafetinib 61 targeted radiotherapeutic 61 Initiates Clinical 61 Phase IIb III 61 MAGE A3 ASCI 61 monoclonal antibody IgG1 Mab 61 systemic anaplastic large 61 ABL inhibitor 61 Capsulitis 61 Proellex TM 61 Phase 1b clinical trials 60 candidate AQ4N 60 telomerase therapeutic 60 oral prodrug 60 GALNS N acetylgalactosamine 60 visit www.genenews.com 60 Phase III Clinical Trial 60 Fx #A 60 Testosterone MDTS ® 60 randomized controlled multicenter 60 novel VDA molecule 60 human IgG1 monoclonal 60 Phase Ib clinical trials 60 signal detection CTSD 60 exploratory Phase IIa 60 ATRA IV 60 SUCCEED trial 60 AN# topical anti 60 induced macular edema 60 IMPACT IMmunotherapy 60 IMPACT DCM 60 metastatic HRPC 60 First Patient Enrolled 60 relapsed refractory multiple myeloma 60 Pruvel ™ 60 ENABLE Phase 2 60 apoptosis inducer 60 Iluvien ® 60 ERBITUX cetuximab 60 Pharmos pipeline 60 NDA Submission 60 agents Tabun Sarin 60 drug pipeline TAFA# 60 IV RSD# 60 personalized cellular immunotherapy 60 mecarbil 60 intravenous belinostat 60 Pivotal Phase III 60 Daclizumab 60 Trial Evaluating 60 novel orally inhaled 60 promotes MERREM ® 60 investigational humanized monoclonal antibody 60 generation URAT1 inhibitor 60 octreotide implant 60 oral Janus kinase 60 phase IIb trial 60 systemic lupus erythematosus rheumatoid 60 docetaxel Taxotere R 60 Presents Positive Preclinical 60 phenylalanine ammonia lyase 60 Telik Announces 60 #-# rDNA origin 60 Hedgehog Pathway Inhibitor 60 BCG refractory carcinoma 60 OLpur TM H2H 60 Pivotal Phase 60 targeted antifolate 60 albiglutide currently 60 generation DACH Platinum 60 dimebon latrepirdine 60 kidney urologic 60 MKC# 60 Custirsen 60 Initiate Clinical Trial 60 successfully commercialize Iluvien 60 Locteron exclusively 60 Randomized Double blind 60 Phase Ia Ib 60 Granted Orphan Drug 60 rusalatide acetate 60 Solazed TM 60 advanced carcinoid 60 XP# XP# 60 including eniluracil ADH 60 AKT inhibitor 60 Files IND 60 oral ridaforolimus 60 data management Clintrial 60 Files Investigational 60 candidate deforolimus 60 Phase Ib clinical 60 Luramist TM 60 Begins Dosing 60 folate analogue metabolic 60 OctoPlus licensed 60 acetonide FA 60 Tarvacin Anti Cancer 60 GVAX R 60 dasatinib Sprycel ® 60 Soliris eculizumab 60 OvaRex R 60 novel histone deacetylase 60 metastatic castrate resistant 59 dextromethorphan quinidine 59 Syncria albiglutide 59 Androxal TM 59 MEND CABG 59 Kosan dependence 59 coronary stent merged 59 agonistic human 59 Phase Ib study 59 AVOREN 59 var arrMeta = 59 EVIZON TM squalamine lactate 59 NPC 1C 59 CB2 selective receptor agonist 59 Exherin TM 59 Ovitrelle R Serostim 59 confirmatory pivotal 59 selective A2A adenosine receptor 59 By JENNIFER LEARN 59 Completes Patient Enrolment 59 receptor tyrosine kinase inhibitor 59 CTA# Injection 59 BioGlue ® 59 PF # [002] 59 Initiated Phase 59 antibody MAb 59 EOquin TM phase 59 clinical trials Archexin ® 59 Phase 2b randomized 59 GATTEX TM 59 NEBIDO VANTAS SUPPRELIN LA 59 metastatic ocular 59 Microplasmin 59 IMA# 59 mitogen activated ERK kinase 59 hormone LHRH antagonist 59 specific CCR9 antagonist 59 REVIVE Diabetes 59 Budesonide foam crofelemer 59 Ostabolin C TM 59 Patient Accrual 59 erlotinib Tarceva R 59 Initiate Phase III 59 Zenvia ™ 59 metastatic hormone refractory 59 recurrent malignant glioma 59 factor TNF receptor 59 delivery polymer matrix 59 nilotinib Tasigna ® 59 rheumatoid arthritis diabetic ulcers 59 MIVI III 59 Submits NDA 59 R pegaptanib sodium 59 orally administered inhibitor 59 Fibrin Pad 59 Auxilium transmucosal film 59 Spectrum Pharmaceuticals Announces 59 XL# XL# XL# 59 Xcellerated T Cells 59 Testosterone MDTS R 59 GATTEX ® 59 EXPLORE Xa 59 Ceflatonin R 59 forodesine purine nucleoside phosphorylase 59 humanized interleukin 6 59 TNFerade ™ 59 SinuNase ™ 59 ZOLL resuscitation product 59 Phase IIb Clinical Trial 59 registrational Phase 59 manufactures minimally invasive 59 developing Bicifadine serotonin 59 Aloprim TM allopurinol sodium 59 highly purified pasteurized 59 Miraxion Amarin lead 59 BIIB# 59 Phase IIb randomized 59 MYDICAR ® 59 pan histone deacetylase 59 multicenter Phase 59 Kit CD# positive 59 evaluating tivozanib 59 decreased matrix metalloproteinase 59 Onyx Pharmaceuticals Announces 59 TASKi2 59 APEX PD 59 Lenocta TM 59 midstage clinical 59 particularly SANCTURA XR 59 Medidur ™ FA 59 MEND CABG II 59 sulfonylhydrazine class 59 investigational oral inhibitor 59 DP VPA 59 label Lipofen R 59 delta opioid receptor 59 GRNOPC1 contains 59 Endologix Powerlink System 59 BLP# Liposome Vaccine 59 cladribine Cladribine Tablets 59 anti atherothrombotic 59 Investigational Oral 59 Receives Orphan Drug Designation 59 generation PNP inhibitor 59 ENRICH trial 59 REG1 Anticoagulation System 59 molecular imaging radiopharmaceutical 59 OAB overactive bladder 59 YONDELIS 59 Xeloda ® 59 oral nucleoside analogue 59 occlusion PAO 59 Medidur TM FA 59 Demonstrates Positive 59 ovarian esophageal 59 include Ischemic Paraplegia 59 Randomized Evaluation 59 influenza BCX# purine nucleoside 58 Cannabinor 58 XOMA 3AB 58 ARIAD Announces 58 palonosetron hydrochloride Injection Dacogen 58 Synta Announces 58 2hours #mins #.#secs M 58 CDK cyclin dependent 58 Europe entitled MINDSET 58 novel nucleoside analog 58 non constipating irritable 58 Receives Milestone Payment 58 pan BCR ABL 58 Levoleucovorin 58 HGS ETR1 mapatumumab 58 PEGylated Fab fragment 58 phase Ib clinical 58 Trofex TM 58 Phase III metastatic melanoma 58 leading oral taxane 58 Syndrome LEMS 58 vapreotide acetate 58 BLA submission 58 collagen sponge seeded 58 immunosuppressive compound 58 Wafer polifeprosan 58 evaluating intravenous picoplatin 58 TM Aganocide 58 R galsulfase 58 BiTE R 58 Peginterferon alfa 2b 58 development peramivir neuraminidase 58 pivotal bioequivalence 58 Aeolus Pharmaceuticals Announces 58 AIMM trial 58 Crowflight Announces 58 HepeX B TM 58 acute peripheral arterial 58 Merck OSI Pharmaceuticals 58 Nasdaq PGNX today 58 Aztreonam lysine 58 AAG KOS 58 PSMA ADC 58 Cloretazine R VNP#M 58 NASH Huntington 58 Aflibercept 58 novel tubulin binding 58 evaluating T DM1 58 inflammatory PDE 58 Novel Oral 58 Patient Registries 58 CAPACITY trials 58 ReN# stem cell 58 AzaSite ISV 58 trastuzumab DM1 T DM1 58 TM Drug Eluting 58 metaglidasen 58 investigational monoclonal antibody 58 metastatic colorectal carcinoma 58 IIa trial 58 ENGINEERING.com Incorporated Announces 58 CYP#A# CYP#D# 58 candidate XP# 58 CCX# B 58 receiving chemoradiation therapy 58 progressive metastatic prostate 58 malignant mesothelioma Alfacell 58 IIa clinical 58 Phase lll 58 CYP#A# isoenzyme 58 investigational pan BCR 58 STOCKS AROUND THE 58 BST CarGel R 58 Phase IIb clinical trials 58 severe hypercholesterolemia 58 IMiDs R 58 AzaSite Plus 58 Receive Milestone Payment 58 relapsed multiple myeloma 58 RTP #i 58 compound INCB# 58 biliary tract cancer 58 histamine dihydrochloride 58 Through Glycoscience R 58 Dupuytren Contracture 58 tumors GIST 58 Pivotal Clinical Trial 58 MCSP respectively 58 Dupuytren Disease 58 SPEAR Study 58 Epothilone D 58 PLK1 SNALP 58 markets COLAZAL 58 multicenter dose escalation 58 PANVAC VF 58 budesonide foam 58 LymphoStat B TM 58 clinic automation LabPas 58 R MSCRAMM 58 Entereg TM 58 PrevOnco ™ 58 GLP toxicology studies 58 DG# compounds targeting 58 Trofex 58 Allos Therapeutics Announces 58 treat chronic sinusitis 58 placebo controlled dose escalation 58 NASDAQ OSIR 58 HRPC ovarian cancer 58 E2F Decoy 58 lead molecular radiotherapeutic 58 Arno Therapeutics 58 trial evaluating PRX# 58 ABSORB clinical 58 JAK2 Inhibitor 57 sarcoma melanoma 57 generation purine nucleoside 57 PNP inhibitor 57 ThermoDox ® clinical 57 rALLy 57 Kinesin Spindle Protein KSP 57 Company Skouries Olympias 57 Zemplar Capsules 57 HGS ETR2 57 essential thrombocythemia ET 57 bapineuzumab AAB 57 candidate TNFerade biologic 57 non metastatic resectable 57 cathepsin K inhibitor 57 ospemifene 57 Curaxin CBLC# 57 Archexin 57 OMP #R# 57 cosmetic cosmeceutical products 57 Fodosine 57 Mg Usa 57 Naglazyme R 57 R#/MEM # 57 IMC #B 57 Pivotal Study 57 oral opioid modulator 57 Vitamin D analogue 57 OSI Eyetech specializes 57 pharmacodynamic profiles 57 vitreoretinal disorders 57 OncoVex 57 TRANSDUR ™ 57 Phase 1b 57 TO AVOID PREGNANCY WHILE 57 cutaneous T 57 phase IIb study 57 peptibody 57 candidate Trofex TM 57 Phase III TRIST 57 Auxilium anticipates 57 investigational antiplatelet agent 57 taxane derivative 57 ocular formulation 57 tiapamil 57 DIRECT Trial 57 Trebuie să te pentru 57 CR# vcMMAE 57 Vitrasert R 57 ATL# [001] 57 Phase Ib 57 Initiate Phase II 57 retinal vein occlusion induced 57 R lenalidomide 57 ANCHOR trial 57 E1 INT TM 57 biologic antibody 57 sunitinib Sutent 57 INTEGRILIN R eptifibatide Injection 57 ELADUR TM 57 candidates Augment ™ 57 Ketotransdel 57 dose escalation clinical 57 Study Evaluating 57 Phase IIB 57 intravenous methylnaltrexone 57 Initiates Phase 2b 57 Xcytrin R 57 antiplatelet compound 57 miconazole Lauriad 57 diets Nevius 57 PREMIERSHIP TOTTENHAM HOTSPUR v 57 Recurrent Glioblastoma 57 tumor activated prodrug 57 ZYBRESTAT fosbretabulin 57 Prostate AdenoCarcinoma Treatment 57 Allovectin 7 R 57 angiotensin analog 57 candidate WF# 57 HepeX B 57 Dose Limiting Toxicity DLT 57 Dose Ranging Study 57 HeartWare System 57 SAR# [004] 57 next generation URAT1 57 CCR9 antagonist 57 phase IIa 57 GEM OS2 57 provides adenoviral reagents 57 selective androgen receptor modulator 57 novel topoisomerase 57 PrevOnco 57 Pralatrexate 57 ongoing Phase 1b 57 Amrubicin 57 novel chimeric natriuretic 57 Chrism Mass marks 57 investigational pharmacologically unique 57 Oral NKTR 57 Hematide ™ 57 Augment Injectable 57 liposomal formulation 57 LifeVantage Announces 57 phase Ib 57 myelofibrosis polycythemia vera 57 NOTE POSIDUR ™ 57 approved incretin mimetic 57 PEGylated docetaxel 57 initiate Phase 1b 57 rheumatoid arthritis RA psoriatic 57 Phase III Trial 57 plus prednisone prednisolone 57 Nymox Reports 57 Unigene nasal calcitonin 57 AVN# Phase 57 toenail onychomycosis 57 By SALLY SPAULDING 57 PRIMO CABG2 57 Acute Myeloid Leukemia AML 57 Janis Joplin soundalike respiratory 57 myocardial infarction ventricular fibrillation 57 Nventa proprietary CoVal 57 anti CD3 monoclonal 57 Panzem R NCD 57 Size LT#/#R-# models 57 confirmatory Phase III 57 Solzira TM 57 advanced metastatic renal 57 Commence Phase 57 Receives CE Marking 57 Nasdaq ETWC leading 57 Eniluracil 57 EMD # 57 relapsed leukemia 57 developed preclinically 57 gastrointestinal GI perforations 57 Somatuline Depot 57 number NCT# ClinicalTrials.gov 57 Multiple Ascending Dose 57 initiated Phase 1b 57 apricitabine ATC 57 VYVANSE TM lisdexamfetamine 57 Targretin capsules 57 Intravenous palifosfamide 57 exemption IDE 57 Veronate R 57 Pivotal Phase II 57 LEVADEX TM 57 Loramyc TM 57 autologous cellular immunotherapy 57 Prodarsan R 57 Phase III ADT 57 Zalypsis 57 Initiates Phase 57 refractory NSCLC 57 Phase IIb Trial 57 Alocrest 57 HCV NS5B polymerase 57 Clinical Trial Evaluating 57 multi kinase inhibitor 57 Panzem R 57 TRANSDUR ® 57 Angiocept 57 cutaneous T cell 57 Omacetaxine 57 Vitaxin 57 Solazed 57 endoscopic autofluorescence imaging 57 Spiegelmer ® 57 PDE4 inhibitor 57 SCIB1 57 novel proprietary KL4 57 Degarelix 57 MEDAREX 57 PRECISE Trial 57 unresectable Stage III 57 Diamyd Medical Diamyd 57 TRACON Pharmaceuticals Inc. 57 ILUVIEN ® 57 CCR5 mAb 57 Serostim ® 57 steroid refractory 56 stage IIIb IV 56 Namenda Memantine HCl 56 candidate Liposomal Grb 56 Oral Fingolimod 56 International SMI SYNN 56 familial amyloidotic polyneuropathy FAP 56 Cleviprex TM clevidipine 56 Luveris R Ovidrel R 56 deCODE AF TM 56 AcryMed Incorporated 56 Novolimus 56 treatment naïve genotype 56 Confirmatory Phase 56 Epeius Biotechnologies Corporation 56 IMC A# 56 miconazole Lauriad R 56 pentadentate logo R 56 Panflu TM Sinovac 56 Phase IIa Clinical Trial 56 Demonstrates Sustained 56 TMC# [002] 56 Pirfenidone 56 catheter occlusion CO 56 systemic Phase 1b 56 candidate CRLX# 56 ACCEDE 56 Enzastaurin 56 carcinoma mCRC 56 evaluating Xcytrin 56 RIGScan TM CR 56 Regenerative Cell 56 phase IIb 56 iii GTx 56 Ganite ® 56 AvalonBay Communities Announces 56 R rilonacept Injection 56 hoFH 56 Sitebrand Announces 56 unresectable locally advanced 56 Kosan proprietary 56 Perifosine KRX 56 topical gel formulation 56 sorafenib tablets 56 Xanafide 56 nalbuphine ER 56 Phase 1a 56 TG MV 56 post operative ileus 56 BR.# 56 candidates Azedra 56 Libby adit 56 Syndax Pharmaceuticals Inc. 56 Tesetaxel 56 By MIKE SACCONE 56 ThermoDox R 56 STOP SHOPPING FOR 56 visit http:/www.clinicaltrials.gov/ 56 SulphCo Announces 56 Panflu TM 56 include Altastaph TM 56 Glufosfamide 56 ragweed allergy immunotherapeutic 56 Pegloticase 56 tramiprosate Alzhemed TM 56 By JENNIFER KOVACS 56 USHE groundbreaking pocket BLU 56 Inc. Nasdaq ATHX 56 Oracea TM 56 hyperplasia BPH 56 Ribavirin causes 56 recurrent glioblastoma multiforme 56 INTERCEPT red 56 ARRY # 56 PROACT Phase 2 56 Sapacitabine 56 NATIONAL ECONOMIC COUNCIL DIRECTOR 56 oral ghrelin agonist 56 DepoCyt ® Abelcet ® 56 Troxatyl 56 CHAMPION PCI 56 PROMACTA ® 56 neuropathic pain spasticity 56 confirmatory clinical 56 individualized cellular immunotherapy 56 Cardioxyl Pharmaceuticals 56 mGluR5 negative 56 Phase Ia 56 antibody MT# 56 non nucleoside HCV 56 cell lymphoma CTCL 56 Randomized Phase 56 Patient Enrolment 56 class mGluR5 inhibitor 56 Phase IIIb 56 HCV RESPOND 2 56 palifosfamide Zymafos TM 56 adjuvant GIST 56 ZOLINZA 56 allosteric modulator PAM 56 therapeutically inactive prodrug 56 TNFerade TM 56 AZX# Phase 56 plus Copegus R 56 PRESEPT 56 peripherally acting 56 Regenerative Cells 56 elderly myelodysplastic syndromes 56 clostridial collagenase 56 CLARITY study 56 Receives Approvable Letter 56 PORxin TM platforms 56 Adjuvant Treatment 56 erlotinib Tarceva ® 56 triggers apoptosis programmed 56 Presents Preclinical Data 56 Peyronie disease Frozen Shoulder 56 thrombin inhibiting aptamer 56 Biliary System 56 JZP 56 BioSante licensees 56 Systemic Delivery 56 Genz # 56 metastatic castration resistant 56 Drug Eluting Stent System 56 EnPro Industries Announces 56 targeted immunotherapies 56 Inc. Nasdaq OXGN 56 R pramlintide acetate 56 Proxinium TM 56 Renewable Ventures Fotowatio 56 Selective Electrochemical Tumor Ablation 56 choriogonadotropin alfa injection 56 CVBT #B 56 Aplidin 56 Patients Treated With 56 ATS Simulus R 56 evaluating mipomersen 56 rhIGF-I/rhIGFBP-3 56 AFREZZA TM 56 R Saizen R 56 Vascular Wrap TM 56 Cardium Therapeutics TM 56 phase III ACCLAIM 56 oral immunomodulatory 56 treat refractory angina 56 SinuNase TM 56 product Abreva ® 56 FavId 56 Lockerby Depth 56 psoriasis rheumatoid arthritis 56 BENLYSTA TM 56 Tutogen utilizes 56 using VIAdel TM 56 placebo controlled multicenter 56 pain palliation 56 Ozarelix 56 multicenter phase 56 subcutaneous PRO 56 5 fluorouracil leucovorin 56 Deforolimus 56 ACTEMRA TM 56 Entereg R 56 Pruvel ™ prulifloxacin 56 Aryplase 56 immunotherapeutic agent 56 keloid scarring 56 Gliadel R 56 Investigational Device Exemption IDE 56 registrational 56 Vasogen Announces 56 bazedoxifene conjugated estrogens 56 Anti VEGF 56 Safinamide 56 topically applied SEPA 56 StemEx 56 Evoltra ® 56 dihydroergotamine mesylate DHE 56 confirmatory Phase 3 56 ALN HTT 56 Aplidin R 56 oncolytic virus therapies 56 Chloride Tl 56 JunJing II 56 uremic pruritus 56 CYTEC INDUSTRIES 56 Phase III 56 use transdermal sumatriptan 56 RECORD1 56 SMA Indústria Química SA 56 Phase 2b Trial 56 MIST II 56 Fibrillex TM 56 ALN TTR# 56 plus prednisone 56 bevirimat Study 56 NU# direct 56 designed chimeric peptide 56 Phase 2b clinical 56 Matt Kenseth Truex 56 carcinoid syndrome 56 Prochymal TM 56 EFAPROXYN 56 fusion enhancers 56 Phase III HEAT 56 Phase IIa trials 56 YOUR LOCAL ANIMAL SHELTER 56 Multicenter Phase 56 BY LEANNE TUCKER ITWEB 56 anticancer compound 56 UPLYSO 56 PINPOINT TM System 56 bile duct tumor 56 DU #b 56 Ridaforolimus 56 Phase 1a clinical 56 memantine HCl 56 Zorbtive TM 56 metastatic colorectal 56 EDEMA3 56 histone deacetylase HDAC inhibitor 56 Medicure Announces 56 unresectable malignant mesothelioma UMM 56 Cutaneous T 56 Biogen Genentech 56 Aurora kinase inhibitor 56 Pain Neutralizer holds 56 includes Prototype Demonstration 56 unpartnered guanosine nucleotide analog 56 enoximone capsules 56 PREOS R 56 dasatinib Sprycel 56 CIMZIA ™ 56 REGEN trial 56 dose escalation phase 56 Albuferon albinterferon alfa 2b 56 Empatic TM 56 include Healive TM 56 causes thick mucus 56 Phase II 56 folinic acid FA 56 placebo controlled randomized 56 Hematide ™ peginesatide 56 allosteric modulator NAM 56 Announces Tentative Approval 56 miconazole Lauriad ® 56 EGS# 56 damaged cirrhotic liver 56 Augment TM 56 Sertraline Hydrochloride Tablets 55 ® natalizumab 55 Phase 2a clinical 55 Clinical Trial Results 55 EOquin TM 55 VICTOR E1 55 Proc Am Soc 55 placebo controlled Phase III 55 GVT BMF & 55 Advanced Melanoma 55 Bioral Amphotericin B 55 VITAL Trial 55 Elagolix 55 lead Aganocide compound 55 soluble tumor necrosis 55 treatment naive genotype 55 Taro Receives 55 BENLYSTA ® 55 HCV polymerase 55 registrational trial 55 Unanimously Recommends Approval 55 CytoFabTM 55 Omnitarg 55 carcinoma HCC 55 AEG# 55 initiate Phase 2b 55 refractory metastatic colorectal cancer 55 BrachySil TM 55 Phase 1b Clinical Trial 55 Sulonex TM 55 GENASIS clinical 55 forodesine 55 refractory multiple myeloma 55 IMiDs ® 55 bardoxolone 55 mesylate tablets fluoroquinolone antibiotic 55 spillway diverts water 55 Phase 2b study 55 AdhTAP 55 Virulizin ® 55 Dyloject TM 55 naïve HCV 55 EmbraceAC 55 sunitinib Sutent ® 55 MT# MEDI 55 QNEXA ® 55 PTH analogue 55 reslizumab 55 OAKLAND ATHLETICS Activated 55 Vicinium TM 55 Vicriviroc 55 controlled multicenter Phase 55 GED aPC 55 AQ4N 55 Gabapentin GR TM 55 Golimumab 55 TURNING INSIGHTS INTO HOPE 55 Plaque Psoriasis 55 prospective randomized multicenter 55 EHT AGN 55 Sturckow eased 55 Besivance 55 torsemide ER